United Kingdom

Nanocarrier signs exclusive agreement with VBL Therapeutics for VB-111 in Japan

Monday, 6 Nov 2017 

Nov 6 (Reuters) - NanoCarrier Co Ltd <4571.T>:Says co signs an exclusive license agreement with VBL Therapeutics, for the development, commercialization, and supply of ofranergene obadenovec ("VB-111") in Japan.Under terms of the agreement, VBL Therapeutics will supply the co with VB-111, and the co will be responsible for all regulatory and other clinical activities necessary for commercialization in Japan.Says VBL Therapeutics will receive up-front payment of $15 million, development and commercial milestone payments and tiered royalties on net sales from the co. 

Company Quote

23 Apr 2019